BIO vs LGVN · rev $651.0M vs rev $2.4M
BIO (BIO) versus Longeveron LLC (LGVN) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Longeveron LLC (LGVN) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported LGVN revenue for 2024-12-31 was $2.4M. Net income was -$16.0M. Revenue was up 237.4% from 2023-12-31 to 2024-12-31. LGVN currently screens at market cap $26.5M.
BIO currently screens at market cap $0. LGVN currently screens at market cap $26.5M.
Not investment advice. Open the BIO and LGVN stock pages for the full models.
Not investment advice.